Skip to main content

#151751

Anti-ASPP1 [ASPP1]

Cat. #151751

Anti-ASPP1 [ASPP1]

Cat. #: 151751

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: ASPP1

Class: Polyclonal

Application: IF ; IP ; WB

Reactivity: Human

Host: Sheep

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: David Elliott

Institute: Newcastle University

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-ASPP1 [ASPP1]
  • Research fields: Cancer;Stem cell biology
  • Clone: ASPP1
  • Tool sub type: Primary antibody
  • Class: Polyclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Sheep
  • Application: IF ; IP ; WB
  • Description: iASPP1 inhibits the proaptotic functions of ASPP1 and p53.
  • Immunogen: Amino acids from human ASPP1 357-532

Target Details

  • Target: ASPP1
  • Target background: Stimulating protein of p53 (ASPP) contains four ankyrin repeats and an SH3 domain involved in protein-protein interactions. ASPP proteins are required for the induction of apoptosis by p53-family proteins. They promote DNA binding and transactivation of p53-family proteins on the promoters of proapoptotic genes. Expression of this gene is regulated by the E2F transcription factor. There are three known types of ASPP: ASPP1, ASPP2 and iASPP1.

Applications

  • Application: IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Thornton et al. 2006. Oncogene. 25(22):3104-12. PMID: 16474851.
  • The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.